First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?

ABSTRACT: Cutaneous melanoma has always been a dreaded diagnosis because of its high mortality rate and its proclivity for invasiveness and metastasis. Historically, advanced melanoma treatment has been limited to chemotherapy and nonspecific immunotherapy agents that display poor curative potential and high toxicity. However, during the last decade, the evolving understanding of the mutational burden of melanoma and immune system evasion mechanisms has led to the development of targeted therapy and specific immunotherapy agents that have transformed the landscape of advanced melanoma treatment. Despite the considerable strides in understanding the clinical implications of these agents, there is a scarcity of randomized clinical trials that directly compare the efficacy of the aforementioned agents;

SUBMITTER: Abdulkarim LS 

PROVIDER: S-EPMC8717133 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature